Does maternal administration of the inactivated influenza vaccine provide passive immunity to the fetus?

Recommendation

Yes—give the inactivated influenza vaccine during pregnancy because it transfers protective maternal IgG to the fetus and protects the infant for the first months of life, improving morbidity and potentially mortality. 1

Rationale grounded in highest-priority evidence

• Guideline (CDC/WHO, 2022): Inactivated influenza vaccine is recommended in any trimester; protection extends to infants via transplacental IgG and also via breastmilk IgA, supporting reduced infant influenza morbidity when infants are too young to be vaccinated (<6 months) 1.
• FDA label (2026): Confirms use in pregnancy registries; highlights higher maternal risk from influenza and adverse pregnancy outcomes if infected—reinforcing the benefit-risk in favor of vaccination for maternal and neonatal outcomes 2.

How fetal/infant protection works

• Placental transfer of maternal IgG after maternal vaccination; higher cord blood titers if vaccinated later in gestation, but earlier vaccination still preferred to prevent severe maternal disease and fetal risks throughout pregnancy 1.
• Breastmilk IgA from vaccinated mothers adds postnatal protection to the infant during early months 1.

Practical algorithm

• Use only inactivated (IM) influenza vaccines during pregnancy; avoid live-attenuated intranasal vaccine (contraindicated) 1.
• Timing:
  • If influenza season is imminent or ongoing: vaccinate now, regardless of trimester (maternal protection + fetal passive immunity) 1.
  • If planning within pregnancy: any trimester acceptable; third-trimester dosing may yield higher cord titers, but do not delay if exposure risk exists earlier 1.
• Postpartum: encourage breastfeeding to extend infant protection via IgA 1.

Nuances, pitfalls, and caveats

• Passive antibody levels wane over months; infant protection is greatest in the first 2–3 months and tapers by 6 months—do not rely on it beyond early infancy; begin routine infant influenza vaccination at ≥6 months 1.
• Do not use live attenuated intranasal vaccine in pregnancy 1.
• FDA labels note limited definitive human developmental risk data but no safety signal and emphasize increased maternal/fetal risk from infection—net benefit remains strongly favorable for morbidity/mortality/QOL 2.

Bottom line for outcomes

• Maternal vaccination reduces severe maternal influenza (lowering maternal morbidity/mortality) and confers passive infant protection during a high-risk, vaccine-ineligible period, improving early-infant morbidity and potentially mortality 1.